109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD